¿Cuál es la utilidad del bloqueo de interleuquina-6 en pacientes con COVID-19?

Contenido principal del artículo

Federico Angriman

Resumen

.

Detalles del artículo

Cómo citar
1.
Angriman F. ¿Cuál es la utilidad del bloqueo de interleuquina-6 en pacientes con COVID-19?. Rev. Hosp. Ital. B.Aires [Internet]. 30 de diciembre de 2021 [citado 20 de julio de 2024];41(4):p. 193-195. Disponible en: //ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/127
Sección
Preguntas al experto

Citas

McElvaney OJ, Curley GF, Rose-John S, et al. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021;9(6):643-654. https://doi.org/10.1016/S2213-2600(21)00103-X.

Angriman F, Ferreyro BL, Burry L, et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med. 2021;9(6):655-664. https://doi.org/10.1016/S2213-2600(21)00139-9.

Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-1244. https://doi.org/10.1016/S2213-2600(20)30404-5.

Zanella A, Florio G, Antonelli M, et al. Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units. Intensive Care Med. 2021;47(9):995-1008. https://doi.org/10.1007/s00134-021-06495-y.

Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72(4):583-589. https://doi.org/10.1136/annrheumdis-2012-202470.

REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502. doi: 10.1056/NEJMoa2100433.

Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20-30. doi: https://doi.org/10.1056/NEJMoa2030340.

Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384(16):1503-1516. https://doi.org/10.1056/NEJMoa2028700.

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645. https://doi.org/10.1016/S0140-6736(21)00676-0.

Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84. https://doi.org/10.1136/bmj.n84.

Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020t;2(10):e603-e612. https://doi.org/10.1016/S2665-9913(20)30277-0.

Gupta S, Wang W, Hayek SS. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41-51. https://doi.org/10.1001/jamainternmed.2020.6252. Errata en: JAMA Intern Med. 2021;181(4):570.

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326(6):499-518. https://doi.org/10.1001/jama.2021.11330.

Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020;370:m3339. https://doi.org/10.1136/bmj.m3339. Errata en: BMJ. 2020;371:m4334.

Artículos más leídos del mismo autor/a

Artículos similares

También puede {advancedSearchLink} para este artículo.